The Chase Group Places VP of Clinical Development and Pharmacovigilance at Marinus Pharmaceuticals
The Chase Group is pleased to continue partnership with Marinus in building their leadership team with the recent placement of the Vice President of Clinical Development and Pharmacovigilance. The successful candidate will be responsible for the medical leadership of the postpartum depression (PPD) programs and drug safety.
This executive’s experience in clinical development within the neuropsychiatric and CNS therapies will be instrumental as Marinus completes its Phase 2 trials in PPD and continues to develop its later-stage development strategy in depression.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.
- Categories: Life Sciences, Pharmaceutical